Danielle Sposato

Key Takeaways MFN-related policy remains a major strategic issue, with panelists describing implications for Medicare, Medicaid, launch pricing, tariffs, and ex-US commercialization decisions. Global pricing decisions are becoming more tightly linked to US market access strategy, particularly as the US is discussed more directly as a reference market.

Key Takeaways Health system specialty pharmacy may play a broader role in value-based care by supporting chronic disease management, not just medication access. High-risk diabetes patients may benefit from more intensive pharmacist-led support, particularly when standard specialty pharmacy services are expanded into care coaching.

Key Takeaways IRA implementation is influencing payer behavior now, particularly in Medicare Advantage and Part D, not just in future pricing cycles. Utilization management is intensifying as plans respond to greater financial exposure for high-cost therapies. High-cost specialty drugs are under the greatest pressure, especially in oncology, immunology, neurology, and other catastrophic-spend categories.